Related Experiment Video
Updated: Dec 2, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
[Current Status of Biomarkers in the Use of Immune Checkpoint Inhibitors]
1Dept. of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University.
Abstract:
Cancer immunotherapy has become a central treatment of cancer with the advent of immune checkpoint inhibitors, and it has caused a paradigm shift in the treatment of cancer. On the other hand, it has been found that only about 10 to 30% of treated patients can obtain the benefit in most cancer types. At present, more than 2,000 clinical trials of combination therapies centering on immune checkpoint inhibitors are being conducted in the hope of further improving the therapeutic effect. A number of combination therapies will be available in the clinic, and a wide range of options will be available in the future. Since it is predicted that direct comparison data will not necessarily be obtained in future treatment options, treatment decisions based on the mechanism and patient status are even more strongly demanded. In addition, identification of biomarkers that can predict therapeutic effects is expected. This article described the current status and prospects of biomarker development in the use of immune checkpoint inhibitors.
Insights
Cancer immunotherapy using immune checkpoint inhibitors offers new hope but benefits only a fraction of patients. Biomarker development is crucial for predicting treatment success and guiding personalized cancer therapy decisions.
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment.
- However, response rates to ICIs remain limited, affecting only 10-30% of patients across most cancer types.
- Numerous clinical trials are exploring ICI combination therapies to enhance efficacy.
Purpose of the Study:
- To review the current landscape and future directions of biomarker development for ICI therapy.
- To emphasize the need for mechanism- and patient-based treatment decisions due to limited comparative data.
- To highlight the importance of predictive biomarkers in optimizing ICI treatment outcomes.
Main Methods:
- Review of current literature on cancer immunotherapy and immune checkpoint inhibitors.
- Analysis of ongoing clinical trials investigating combination therapies.
- Discussion on the role and development of predictive biomarkers.
Main Results:
- Limited patient benefit from current ICIs necessitates further therapeutic strategies.
- Over 2,000 clinical trials are investigating ICI combination therapies.
- Biomarker identification is critical for predicting treatment response and guiding clinical decisions.
Conclusions:
- Personalized treatment strategies based on patient status and tumor biology are essential.
- Biomarker development is key to improving the effectiveness of cancer immunotherapy.
- Future cancer treatment decisions will increasingly rely on predictive biomarkers and mechanistic understanding.
